Xanthohumol

Xanthohumol has demonstrated potent antiproliferative activity in vitro across breast, colon, prostate, and ovarian cancer cell lines (IC50 values of 1–20 µM in most studies). In a Phase I dose-escalation human study (Hussong et al., 2018), XN at 24–120 mg/day for 6 weeks was well-tolerated with favorable pharmacokinetics; however, plasma concentrations achieved were substantially below those required for anticancer effects observed in vitro, raising questions about in vivo efficacy at achievable oral doses. A rodent RCT showed XN supplementation (30 mg/kg/day) significantly reduced body weight, fasting glucose, and LDL-C versus controls over 12 weeks, with AMPK activation confirmed in liver tissue.

Xanthohumol demonstrates broad preclinical anticancer activity across multiple tumor types (breast, colon, prostate, hepatocellular) with mechanistic plausibility. However, bioavailability from beer is poor (extensive first-pass metabolism), and therapeutic doses in humans would require concentrated extract supplementation. A Phase I clinical trial evaluating xanthohumol pharmacokinetics in healthy volunteers showed rapid clearance and extensive conjugation, limiting systemic exposure from dietary sources.